← Back to Screener
Kodiak Sciences Inc Common Stock (KOD)
Price$46.44
Favorite Metrics
Price vs S&P 500 (26W)269.52%
Price vs S&P 500 (4W)92.30%
Market Capitalization$2.78B
All Metrics
Book Value / Share (Quarterly)$2.55
P/TBV (Annual)0.32x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-2.21
Price vs S&P 500 (YTD)56.45%
EPS (TTM)$-4.32
10-Day Avg Trading Volume0.99M
EPS Excl Extra (TTM)$-4.32
EPS (Annual)$-4.32
ROI (Annual)-89.35%
Cash / Share (Quarterly)$3.40
ROA (Last FY)-65.42%
EBITD / Share (TTM)$-4.06
ROE (5Y Avg)-95.63%
Cash Flow / Share (Annual)$-2.21
P/B Ratio17.64x
P/B Ratio (Quarterly)10.85x
Net Income / Employee (Annual)$-2
Net Interest Coverage (TTM)-10.74x
ROA (TTM)-81.82%
EPS Incl Extra (Annual)$-4.32
Current Ratio (Annual)4.72x
Quick Ratio (Quarterly)4.61x
3-Month Avg Trading Volume1.07M
52-Week Price Return1802.54%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$5.76
52-Week High$46.67
EPS Excl Extra (Annual)$-4.32
CapEx CAGR (5Y)-40.87%
26-Week Price Return278.26%
Quick Ratio (Annual)4.61x
13-Week Price Return56.61%
Total Debt / Equity (Annual)0.64x
Current Ratio (Quarterly)4.72x
Enterprise Value$2,667.107
Book Value / Share Growth (5Y)-31.46%
Revenue / Employee (Annual)$0
Cash / Share (Annual)$3.40
3-Month Return Std Dev170.04%
Net Income / Employee (TTM)$-2
ROE (Last FY)-146.12%
Net Interest Coverage (Annual)-12.90x
EPS Basic Excl Extra (Annual)$-4.32
Total Debt / Equity (Quarterly)0.64x
EPS Incl Extra (TTM)$-4.32
ROI (TTM)-121.00%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$8.33
Price vs S&P 500 (52W)1767.45%
Year-to-Date Return60.59%
5-Day Price Return7.03%
EPS Normalized (Annual)$-4.32
ROA (5Y Avg)-50.38%
Month-to-Date Return17.79%
Cash Flow / Share (TTM)$-4.89
EBITD / Share (Annual)$-4.06
LT Debt / Equity (Annual)0.64x
ROI (5Y Avg)-69.55%
LT Debt / Equity (Quarterly)0.64x
EPS Basic Excl Extra (TTM)$-4.32
P/TBV (Quarterly)0.46x
P/B Ratio (Annual)10.85x
Book Value / Share (Annual)$2.55
Price vs S&P 500 (13W)53.74%
Beta2.35x
Revenue / Share (TTM)$0.00
ROE (TTM)-255.37%
52-Week Low$2.17
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
3.75
3.83
4.00
4.00
Industry Peers — Biological Products(89)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
KODKodiak Sciences Inc Common Stock | — | — | — | — | $46.44 |
AMGNAmgen Inc | 5.20x | 9.95% | 73.30% | 2.93% | $350.16 |
GILDGilead Sciences Inc | 5.71x | 2.40% | 78.83% | 133.64% | $135.87 |
ARGXargenx SE American Depositary Shares | 12.59x | 89.56% | 150.91% | — | $834.45 |
BNTXBioNTech SE American Depositary Share | 9.06x | -11.81% | 84.21% | — | $105.19 |
BIIBBiogen Inc. Common Stock | 2.72x | 2.22% | 75.69% | -18.77% | $183.34 |
MRNAModerna, Inc. Common Stock | 10.91x | -39.93% | 70.32% | — | $54.59 |
NBIXNeurocrine Biosciences Inc | 4.64x | 21.45% | 98.18% | 2.31% | $131.59 |
EXELExelixis Inc | 4.89x | 6.85% | 96.39% | 31.10% | $43.61 |
TECHBio-Techne Corp. | 7.72x | 1.64% | 66.60% | -20.58% | $60.58 |
IBRXImmunityBio, Inc. Common Stock | 74.42x | 668.31% | 99.34% | — | $8.20 |
About
Kodiak Sciences is a biopharmaceutical company developing novel therapeutics for high-prevalence retinal diseases, with a focus on wet age-related macular degeneration. The company's clinical-stage pipeline includes an antibody biopolymer conjugate for previously untreated wet AMD patients, along with additional candidates such as Tarcocimab tedromer, KSI-501, and KSI-101. These programs target significant unmet needs in retinal disease treatment.